Altered Levels and Isoforms of Tau and Nuclear Membrane Invaginations in Huntington's Disease
- PMID: 32009905
- PMCID: PMC6978886
- DOI: 10.3389/fncel.2019.00574
Altered Levels and Isoforms of Tau and Nuclear Membrane Invaginations in Huntington's Disease
Abstract
Since the early reports of neurofibrillary Tau pathology in brains of some Huntington's disease (HD) patients, mounting evidence of multiple alterations of Tau in HD brain tissue has emerged in recent years. Such Tau alterations range from increased total levels, imbalance of isoforms generated by alternative splicing (increased 4R-/3R-Tau ratio) or by post-translational modifications such as hyperphosphorylation or truncation. Besides, the detection in HD brains of a new Tau histopathological hallmark known as Tau nuclear rods (TNRs) or Tau-positive nuclear indentations (TNIs) led to propose HD as a secondary Tauopathy. After their discovery in HD brains, TNIs have also been reported in hippocampal neurons of early Braak stage AD cases and in frontal and temporal cortical neurons of FTD-MAPT cases due to the intronic IVS10+16 mutation in the Tau gene (MAPT) which results in an increased 4R-/3R-Tau ratio similar to that observed in HD. TNIs are likely pathogenic for contributing to the disturbed nucleocytoplasmic transport observed in HD. A key question is whether correction of any of the mentioned Tau alterations might have positive therapeutic implications for HD. The beneficial effect of decreasing Tau expression in HD mouse models clearly implicates Tau in HD pathogenesis. Such beneficial effect might be exerted by diminishing the excess total levels of Tau or specifically by diminishing the excess 4R-Tau, as well as any of their downstream effects. In any case, since gene silencing drugs are under development to attenuate both Huntingtin (HTT) expression for HD and MAPT expression for FTD-MAPT, it is conceivable that the combined therapy in HD patients might be more effective than HTT silencing alone.
Keywords: huntington’s disease; tau; tau nuclear indentation (TNI); tau nuclear rod (TNR); tauopathy.
Copyright © 2020 Fernández-Nogales and Lucas.
Figures

Similar articles
-
Faulty splicing and cytoskeleton abnormalities in Huntington's disease.Brain Pathol. 2016 Nov;26(6):772-778. doi: 10.1111/bpa.12430. Brain Pathol. 2016. PMID: 27529534 Free PMC article. Review.
-
Tau-positive nuclear indentations in P301S tauopathy mice.Brain Pathol. 2017 May;27(3):314-322. doi: 10.1111/bpa.12407. Epub 2016 Aug 2. Brain Pathol. 2017. PMID: 27338164 Free PMC article.
-
Differential Regulation of Tau Exon 2 and 10 Isoforms in Huntington's Disease Brain.Neuroscience. 2023 May 10;518:54-63. doi: 10.1016/j.neuroscience.2022.07.014. Epub 2022 Jul 19. Neuroscience. 2023. PMID: 35868517
-
Huntington's disease is a four-repeat tauopathy with tau nuclear rods.Nat Med. 2014 Aug;20(8):881-5. doi: 10.1038/nm.3617. Epub 2014 Jul 20. Nat Med. 2014. PMID: 25038828
-
[The genetics of dementias. Part 1: Molecular basis of frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17)].Postepy Hig Med Dosw (Online). 2009 Jun 15;63:278-86. Postepy Hig Med Dosw (Online). 2009. PMID: 19535823 Review. Polish.
Cited by
-
Gene targeting techniques for Huntington's disease.Ageing Res Rev. 2021 Sep;70:101385. doi: 10.1016/j.arr.2021.101385. Epub 2021 Jun 5. Ageing Res Rev. 2021. PMID: 34098113 Free PMC article. Review.
-
Targeting Tau to Treat Clinical Features of Huntington's Disease.Front Neurol. 2020 Nov 19;11:580732. doi: 10.3389/fneur.2020.580732. eCollection 2020. Front Neurol. 2020. PMID: 33329322 Free PMC article. Review.
-
Mechanics and functional consequences of nuclear deformations.Nat Rev Mol Cell Biol. 2022 Sep;23(9):583-602. doi: 10.1038/s41580-022-00480-z. Epub 2022 May 5. Nat Rev Mol Cell Biol. 2022. PMID: 35513718 Free PMC article. Review.
-
Tau: a biomarker of Huntington's disease.Mol Psychiatry. 2023 Oct;28(10):4070-4083. doi: 10.1038/s41380-023-02230-9. Epub 2023 Sep 25. Mol Psychiatry. 2023. PMID: 37749233 Review.
-
Implications of Tau Dysregulation in Huntington's Disease and Potential for New Therapeutics.J Huntingtons Dis. 2023;12(1):1-13. doi: 10.3233/JHD-230569. J Huntingtons Dis. 2023. PMID: 37092231 Free PMC article. Review.